Navigation Links
SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
Date:6/13/2008

DUBLIN, Calif., June 13 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, that its lead, oral PIM kinase inhibitor, SGI-1776, causes tumor regression in acute myologenous leukemia (AML) xenograft models (abstract #744).

In a poster presentation entitled "A potent small molecule PIM kinase inhibitor with in vivo oral availability and activity in cell lines from hematological malignancies," Dr. Gregory Berk, SuperGen's Chief Medical Officer, detailed how scientists used SuperGen's CLIMB(TM) technology to build a model that allowed for the creation of small molecule PIM kinase inhibitors. SGI-1776 was identified as an orally available, potent and selective inhibitor of the PIM kinases. SGI-1776 induces cell cycle arrest, dose dependent apoptosis and a reduction in phospho-BAD levels in leukemia and lymphoma cell lines. Phospho-BAD is a direct substrate for PIM, and may serve as a useful in vivo biomarker for future clinical trials. Most notably, SGI-1776 induced significant tumor regression in MOLM-13 and MV-4-11 (AML) xenograft models.

"Our PIM kinase inhibitor, SGI-1776, has the potential to be an effective treatment for AML and other malignancies that over-express PIM kinase," said Dr. James Manuso, SuperGen's President and Chief Executive Officer. "The data also provide support for the use of our CLIMB(TM) technology to identify and rapidly advance candidates into the clinic. We plan to initiate Phase 1 clinical trials with SGI-1776 in solid tumors and leukemias later this year. SGI-1776 may become the first drug in this class of inhibitors to enter the clinic."

SuperGen's schedule of presentations at EHA is as follows:

Date Time (PDT) Abstract # and Title

Friday, June 13 8:45 a.m.-10 a.m. #744 - A potent small molecule PIM

kinase inhibitor with in vivo oral

availability and activity in cell

lines from hematological

malignancies

Sunday, June 15 1:30 a.m.-2:45 a.m. #741 - SGI-1252: A potent small

Oral Presentation molecule JAK2 inhibitor

Hall C5

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development Tel: (925) 560-2845

Tel: (925) 560-0100 E-mail: mary.vegh@supergen.com

E-mail: tenns@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
4. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
5. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
6. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
9. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
10. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
11. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... May 23, 2016 Non-invasive diagnostic ... of multiple diseases; ,Technology to be presented at Yissum’s ... Yissum Research Development Company of the Hebrew University of ... research agreement with Aurum Ventures MKI, the technology investment arm ... a new diagnostic approach for early detection of multiple ...
(Date:5/23/2016)... May 23, 2016 Gamida Cell, ... treatment of cancer and orphan genetic diseases, announced today ... $4.4 million from the Israel Innovation Authority (formerly the ... of Economy and Industry. The mission of the Israel ... various industries, including science and technology, while stimulating economic ...
(Date:5/23/2016)... 2016   Purdue Pharma L.P.  today announced ... with Egalet Corporation and Acura Pharmaceuticals, Inc. that ... the agreement the companies will exchange valuable patent ... companies to develop and sell several opioid pain ... reflects the commitment of Purdue Pharma to seek ...
Breaking Medicine Technology:
(Date:5/24/2016)... Indianapolis, IN (PRWEB) , ... May 24, 2016 ... ... employee benefits advisory organization, is pleased to welcome new Partner Firm Austin & ... a personalized, consultative approach to insurance, employee benefits, HR consulting, benefits technology, and ...
(Date:5/24/2016)... ... May 24, 2016 , ... New Brunswick, New Jersey: This year ... needs reach their fullest potential. To commemorate the anniversary, the hospital has themed the ... n’ Roll for Children’s Specialized Hospital Foundation on Saturday, May 21, at Johnson Park ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... for physical disease or injury that focuses on repairing the musculoskeletal and neuromuscular ... With an emphasis on functional restoration, NYDNRehab began providing treatments for physical therapy ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Growing in popularity, ... trend, more gluten-free products are available and easily accessible. Whether someone chooses to cut ... cater to a certain diet, King Kullen Grocery stocks their shelves with many different ...
(Date:5/24/2016)... OR (PRWEB) , ... May 24, 2016 , ... ... welcomed Peggy Kinst, a wellness specialist for forty years and a trainer for ... the Sharon Kleyne Hour Radio Talk Show on May 16, 2016. , Formerly ...
Breaking Medicine News(10 mins):